Safety and Efficacy Study of S-309309 in Obese Adults

Korábbi kezelés

• A severe psychiatric condition, such as schizophrenia, bipolar disorder, or major depression in the previous 2 years before the Screening Visit, or history of treatment with antipsychotics, antidepressants, or mood stabilizers in the previous 2 years before the Screening Visit.
• Suicidal ideation corresponding to type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past 30 days prior to the Screening Visit
• A self-reported change in body weight > 5 kg (11 pounds [lbs]) within 90 days prior to the Screening Visit
• Marijuana use within 90 days prior to the Screening Visit
• Use of medications that the investigator considers to be associated with weight changes within 90 days prior to the Screening Visit
• Concomitant or previous steroid treatments (including eye-drops, inhalers, and nebulizers) for a total of ≥ 15 days during the 24 weeks prior to the Screening Visit; dermatological preparations of steroids will be allowed
• Concomitant use of any dietary or herbal supplement that is indicated for weight management or maintenance of healthy weight
• Use of drugs or substances known to be inducers or inhibitors of P-glycoprotein (P-gp) within 28 days prior to dosing
• Received any investigational drug within 3 months of the Screening Visit
• History of coronavirus disease 2019 (COVID-19) infection within 14 days prior to the Screening Visit or close contact with a COVID-19 patient in the 14 days prior to the Screening Visit as reported by the participant and the participant's medical history
• Presence of HIV antibody at the Screening Visit or within 90 days prior to the Screening Visit

Más betegség

• Obesity of known endocrine origin (eg, untreated hypothyroidism, Cushing's syndrome)
• Any lifetime history of a suicide attempt or history of any suicidal ideation within the past year before entry into the study
• History of documented human immunodeficiency virus (HIV) infection
• History of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
• History of inflammatory conditions and autoimmune diseases
• Active malignancy or history of malignancy (other than nonmelanoma skin cancer or any grade intraepithelial cervical neoplasia that has been surgically treated) within 5 years of enrollment in this study
• History of an eating disorder (eg, bulimia or anorexia nervosa)
• History of drug or alcohol abuse within 5 years of the Screening Visit
• Known history of treated or untreated diabetes
• Chronic history of or current liver disease or known hepatic or biliary abnormalities (with the exception of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, Gilbert's syndrome or gallstones)
• History of or planned bariatric surgery or intra-abdominal balloon during study participation
• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy, that, in the opinion of the investigator or medical monitor, contraindicates participation in the study

Laborértékek

• Males: a QT interval corrected using Fridericia's formula (QTcF) interval of > 450 msec at the Screening Visit; females: a QTcF interval > 470 msec at the Screening Visit
• Baseline hemoglobin A1c (HbA1c) ≥ 6.5% at the Screening Visit
• Alanine aminotransaminase (ALT) > 3 × upper limit of normal (ULN) at the Screening Visit
• Aspartate aminotransaminase (AST) > 3 × ULN at the Screening Visit
• Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m\^2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) at the Screening Visit
• Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration < 11.5 g/dL for males, < 10.5 g/dL for females) at the Screening Visit or any other condition known to interfere with interpretation of HbA1c measurement
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Egyéb

• Medical history or characteristics suggestive of genetic obesity
• A Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15 at the Screening Visit
• Any underlying lens opacity that affects the BCVA, or any posterior subcapsular opacity ≥ P1 based on the LOCS III, even if not impacting the BCVA
• Regularly consumes excessive amounts of alcohol, defined as > 3 glasses of alcoholic beverages per day
• Female study participants who have a positive urine pregnancy test at the Screening Visit
• Female study participants who are breastfeeding
• Poor venous access based on the investigator's judgement
• Unable to swallow capsules

• BMI of ≥ 30 kg/m\^2 (obese) with or without comorbidities. An online BMI calculator is available at Calculate Your BMI - Standard BMI Calculator (nih.gov)
• Stable body weight (defined as ≤ 5 kg of self-reported change) within 90 days prior to study start
• Lifetime history of at least 1 unsuccessful dietary effort to lose body weight
• Is a participant of non-childbearing potential (PONCBP) OR Is a participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective as specified in the protocol. A POCBP must have a negative highly sensitive pregnancy test (urine or serum) before a first dose of study intervention as per protocol.